Sareum Holdings granted patents in Japan and Singapore
Updated : 15:01
Specialist cancer drug discovery and development company Sareum announced on Monday that the Japan and Singapore Patent Offices have issued notifications that patents will be granted for inventions associated with its Aurora+FLT3 kinase inhibitor programme.
The AIM-traded firm said the patents describe compounds that inhibit the activity of Aurora and FLT3 kinase enzymes and the medical use of these compounds, particularly in the treatment of cancer.
It said the granting of the patent in Japan means that Sareum will now have approved patent protection in all major territories for its Aurora+FLT3 kinase inhibitor programme.
The company announced that similar patents were to be granted in the USA and Europe in September 2015 and in China in August 2016.
Sareum's Aurora+FLT3 kinase inhibitor programme targets acute myeloid leukaemia, its board explained, as well as other leukaemias and lymphomas.
“These notifications of patent grants in Japan and Singapore complete the protection of the intellectual property associated with Sareum's Aurora+FLT3 programme in all the major territories, enhancing our negotiating position with potential licence partners,” said Sareum CSO Dr John Reader.